Halozyme Therapeutics Inc (HALO)

[maumar]

One of the reasons is probably the patent cliffs. It would be interesting to know why Astra Zeneca chose Alteogen over Halo since I don't think there was an issue with exclusivity. It could be the patent issue. It could also be that they either got better terms or they think Alteogen has a better product, or a combination of the two.

The issue of the lack of significant deals is reflected in the stock action. Halo hit $50 at the beginning of 2021 and right now it is below the $59.44 high of November 2022. Buy and hold has not worked well for Halo shareholders in the past four years or so in spite of the fact that revenues and earnings have exceeded expectations. If we had sold in 2021 and bought the SPY, or even treasuries, we would have done a lot better and with a lot less risk.